CVS Health has said it will remove AbbVie’s big-selling immunology drug Humira from most of its national formulary lists of reimbursable products, and offer biosimilar ver
The Biden administration has generated a list of 48 drugs whose prices were raised faster than inflation in the last quarter of this year and may be subject to the mandato
Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than
The White House said today that it may take enforced ownership of patents on medicines developed with public funding if their manufacturers set their prices too high.
The pharma industry and the UK government may have reached an accord on the voluntary scheme of rebates used to limit rises in medicines spending in the UK, but the altern
Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufac